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Abstract
[VO(Sal-L-tryp)(H2O)] 1 (where sal-L-tryp = N-salicylidene-L-tryptophanate) was used as a
precursor to produce the novel complexes, [VO(Sal-L-tryp)(MeATSC)].1.5C2H5OH 2 (where
MeATSC = 9-Anthraldehyde-N(4)-methylthiosemicarbazone), [VO(Sal-L-tryp)(N-
Ethhymethohcarbthio)].H2O 3 (where N-Ethhymethohcarbthio = (E)-N-ethyl-2-(4-hydroxy-3-
methoxybenzylidene)hydrazinecarbothioamide), and [VO(Sal-L-tryp)(acetylethTSC)].C2H5OH 4
(where acetylethTSC = (E)-N-ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide), by
reaction with the respective thiosemicarbazone. The chemical and structural properties of these
ligands and complexes were characterised by elemental analysis, ESI MS, FT-IR, UV-visible,
ESR, 1H and 13C NMR spectroscopy, and X-ray crystallography. DMSO and DMSO-d6 solutions
of compounds 1-4 were oxidised in air to produce vanadium(V) species which were verified by
ESI MS and 51V NMR spectroscopy. Anti-cancer properties of compounds 2-4 were examined
with three colon cancer cell lines, HTC-116, Caco-2, and HT-29, and also with non-cancerous
colonic myofibroblasts, CCD18-Co. Compounds 2-3 exhibited less inhibitory effects in the
CCD-18Co cells, indicating a possible cytotoxic selectivity towards colon cancer cells. In general,
those compounds which exhibited anti-proliferative activity on cancer cells, but did not affect non-
cancerous cells, may have a potential in chemotherapy.
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Introduction
The limited efficacy of current treatments for advanced colon cancer serves an impetus for a
concerted effort to identify chemo-preventive agents for treatment. This process has always
involved metal complexes. Cisplatin is widely used for the treatment of many cancers[1]
despite its high toxicity, undesirable side effects, and problems with drug resistance in
primary and metastatic cancers.[2] These limitations have spurred a growing interest in novel
non-platinum metal complexes that can show anti-cancer properties.[3] Ruthenium has been
reported to possess several favourable properties suited to rational anti-cancer drug design[4]
and ruthenium complexes of various types are actively studied as metallodrugs as they are
believed to have low toxicity and good selectivity for tumours.[5] Recently, we reported the
effect of ruthenium(II) complexes with new chelating thiosemicarbazones on growth
inhibition of MCF-7 and MDA-MB-231 (breast adenocarcinoma) as well as HCT 116 and
HT-29 (colorectal carcinoma) cell lines.[6] Thiosemicarbazones and their metal complexes
are used in many applications ranging from pharmacology to nuclear medicine.[7]
Here we present our efforts to expand our study to the non-ruthenium systems. There have
been few systematic studies of the use of vanadium compounds as potential anti-cancer
agents, for example, there was a report of vanadium(V) complexes with salicylaldehyde
semicarbazone derivatives featuring in vitro anti-tumour activity towards kidney tumour
cells (TK-10).[8] Also, several vanadium(IV) compounds are known to exhibit anti-cancer
activities.[9] Previously, bis(4,7-dimethyl-1,10-phenanthroline)sulfatooxovanadium(IV)
(metvan) was identified as the most promising multi-targeted anti-cancer compound with
apoptosis-inducing activity.[9c]
Interestingly, in this study, metvan was found to be highly effective against cisplatin-
resistant ovarian and testicular cancer cell lines.[9c] Given the paucity of data regarding the
use of vanadium(IV) complexes with thiosemicarbazones as ligands, as potential anti-cancer
agents, we now describe in this report the synthesis and chemical characterisation of a series
of such complexes and the preliminary results of a biological study against several colorectal
cancer cell lines in order to evaluate their potential as chemotherapeutic candidates.
Chemistry and pharmacology
9-Anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) was synthesised as by
Beckford et al.;[6] while two novel thiosemithiocarbazones (E)-N-ethyl-2-(4-hydroxy-3-
methoxybenzylidene)hydrazinecarbothioamide (N-Ethhymethohcarbthio) and (E)-N-
ethyl-2-(1-(thiazol-2-yl)ethylidene)hydrazinecarbothioamide (acetylethTSC) were also
synthesised (Scheme S1, Supporting Information). 2-(2-Hydroxybenzylamino)-3-(1H-
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indol-3-yl)propanoic acid (the reduced Schiff base) was prepared using a known
procedure[10] involving salicylaldehyde, amino acids, and NaBH4, but with L-tryptophan
(Scheme S2, Supporting Information). [VO(Sal-L-tryp)(H2O)] 1 (where sal-L-tryp = N-
salicylidene-L-tryptophanate) was prepared as by Pessoa et al.[11] [VO(Sal-L-tryp)
(MeATSC)].1.5C2H5OH 2, [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O 3, and
[VO(Sal-L-tryp)(acetylethTSC)].C2H5OH 4 were synthesised by reacting [VO(Sal-L-tryp)
(H2O)] 1 and the respective thiosemicarbazones (Scheme 1). Compounds 2–4 were isolated
in yields ranging from 57 to 78%.
In the present study, we investigated the cytotoxic effects of our complexes against three
colon cancer cell lines, HTC-116, Caco-2, and HT-29, along with a comparative anti-
proliferative study on non-cancerous colonic myofibroblasts, CCD-18Co using the standard
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-
tetrazolium, inner salt]-dye reduction assay for cell viability.
Results and Discussion
All compounds were characterised by elemental analysis. The structural components of the
ligands and complexes were confirmed by FT IR spectroscopy, 1H and 13C NMR
spectroscopy, mass spectroscopy, and X-ray crystallography, where appropriate.
Elemental and Mass spectroscopic analyses
Elemental analyses were carried out on N-Ethhymethohcarbthio and compounds 1–4. The
percentage of N found in compound 4 was 10.91% versus the calculated value of 12.98%.
The elemental analysis data for the percentage of N is not fully consistent with the
calculated value, but other spectroscopic methods have confirmed the identity of compound
4. Due to the fact that the discrepancy is only in the nitrogen, it is more likely due to an error
in the analysis process, or the loss of ethanol as solvate during the analytical procedure.
However, ESI MS analysis proved the existence of the complex [VO(Sal-L-tryp)
(acetylethTSC)] without any ethanol as a solvate.
ESI mass spectra were acquired for compounds 2–4 and the products obtained from oxidised
DMSO solutions of compounds 1 and 3 (Figures S1–S9, and Schemes S3–S5 for the
respective spectra and proposed fragmentation patterns, Supporting Information). The
results thus obtained are in agreement with metal/ligand ratio 1:1 in the investigated
complexes. Table 1 shows the ESI MS data acquired for the respective ligands and
complexes (see Figures S1–S9, Supporting Information). Overall, the suggested formulae
were further confirmed by mass spectral fragmentation analysis.
Oxidovanadium(IV) complexes that contain N-salicylidene-L-aminoacidatos ligands can be
oxidised to form vanadium(V) compounds.[12] It is important to determine whether our
vanadium(IV) complexes can be oxidised to form vanadium(V) species when dissolved in
DMSO. Compounds 1 and 3 were dissolved in DMSO, and the resulting solutions were
allowed to evaporate to leave a solid. ESI mass spectral studies were carried out on the
remaining solids. In our study, we have found out that compounds 1 and 3 were oxidised to
form vanadium(V) species (see Table 1). Vanadium(V) species with coordinated DMSO
were detected from ESI MS studies. Scheme 2 shows a proposed mechanism for the
formation of the oxidised compounds in DMSO.
X-ray crystallographic studies on acetylethTSC
A single crystal of acetylethTSC was grown by slow evaporation of a methanol solution.
The molecular structure of acetylethTSC, together with the atomic numbering scheme is
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shown in Figure 1, while Table 2 shows its crystal data and structure refinement (See Tables
S1-S5, Supporting Information, for selected bond lengths and angles).
Thiosemicarbazones are known to exhibit thione-thiol tautomerism.[6] The Ortep diagram
shows that acetylethTSC exists as a thione in the solid state. The C(1)-S(1) distance (1.6814
Å) is similar to that found in a methyl analogue of 2-acetyl-2-thiazoline thiosemicarbazone
which is in the thione form as a solid.[13] AcetylethTSC adopts a syn conformation about the
N1–N2 bond in a similar fashion as those thiosemicarbazones that were formed from 2-
acetylthiazole as reported by Venkatraman et al.[14] The N2-H group donates an
intermolecular hydrogen bond to thione S1, while forming centrosymmetric hydrogen-
bonded dimers with N…S distance 3.4651(15) Å. Thiazole N atom N4 is not involved in
hydrogen bonding as shown in Figure 2.
FT IR Spectroscopy
Infrared spectra were acquired for the ligands and complexes (see Figures S10-S18,
Supporting Information). Thiosemicarbazones exhibit characteristic bands corresponding to
various functional groups in different energy regions. The most significant infrared bands in
the region 4000–500 cm-1 are found between 3100–3500 (assigned to NH stretching
vibrations); 1580–1630 (assigned to C=N + NH); and 1100–1300 and 820–900 (assigned to
the C=S moiety). Thiosemicarbazones can coordinate as either a neutral (thione) or as a
mono-anionic (thiolate) ligand.[15] The ligands (see Figures S10-S12, Supporting
Information) in our case all seem to be in the thione form in the solid state [16]. This can be
inferred primarily from the absence of a ν(S-H) absorption in the region 2600–2500 cm-1.
There are two bands in the ν(N-H) region and the presence of the peak due to the hydrazinic
hydrogen confirms the thione formulation. The thiolate form was not evident in our
compounds (see tables 3 and 4 for the respective stretching frequencies for the ligands and
complexes) in the solid state.
Infrared spectra of all the complexes (see Figures S15-S18, Supporting Information) show a
band in the ν(N-H) region which may be attributed to the hydrazinic nitrogen thus
suggesting that the ligands are coordinated as the thione form. It must be noted that neither
the hydrazinic nor the terminal (aminic) hydrogen has shifted significantly upon
coordination of the ligand. The ligands all show a medium intensity band in the 1620–1605
cm-1 region, and this is assigned as the C=N (imine) linkage. On coordination of the ligand,
this band shifts significantly for the acetylethTSC ligand (1607 to 1621 cm-1 in compound
4) and for the N-Ethhymethohcarbthio ligand (1605 to 1616 cm-1 in compound 3) ligands.
The stretching frequency of the MeATSC ligand changed slightly on coordination to
compound 1. The shift in this band is indicative of the iminic nitrogen being involved in the
ligation.[7b, 17] The involvement of the thiocarbonyl group in binding can be similarly
inferred from the fact that the peaks due to frequency changes to lower wave numbers (6
cm-1 for compound 2, 11 cm-1 for compound 3, and 2 cm-1 for compound 4) on coordination
of the respective ligands to compound 1. The magnitude of the shifts suggest that the ligands
coordinate as the neutral, bidentate (through the iminic nitrogen and the thiocarbonyl
sulphur) form in all the complexes.
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A ν(V-S) stretching frequency is observed in the region 470 – 400 cm-1 for all complexes.
The absence of a similar band in the spectra of the free thiosemicarbazone ligands, confirms
coordination via the thiocarbonyl sulphur atom. IR spectra of the reduced Schiff base and
K[Sal-L-tryp)] (see Figures S13 and S14, Supporting Information) are used to assign the
important stretching frequencies due to the coordination of the Schiff base moiety. A
phenolate ν(C-O) stretching frequency in the region 1545-1540 cm-1 is observed for
compounds 1–4. A broad ν(OH) stretching frequency is observed at 3014, 3010, and 3256
cm-1 for compounds 1 and 3, respectively. The absence of phenol’s ν(OH) stretching
frequencies in compounds 2 and 4 confirms coordination of the ligand to the vanadium(IV)
metal centre via the phenolate anion.[18]
All complexes exhibited ν(V=O) stretching frequencies in the region 997–980 cm-1, which
is the typical range for oxidovanadium(IV) complexes.[19] Upon coordination of the
respective thiosemicarbazone ligands to compound 1, a lowering of the V=O stretching
frequency occurred, for example, a change of 17 cm-1 in compound 2, 21 cm-1 in compound
3, and 15 cm-1 in compound 4.
NMR spectral studies
1H and 13C NMR spectroscopy—1H and 13C NMR spectra were acquired for N-
Ethhymethohcarbthio ligand, acetylethTSC, the reduced Schiff base, K[Sal-L-tryp)], and the
oxidized products derived from compounds 1 and 3 (Figures S19-S26, Supporting
Information). Figure 3 shows the 1H NMR spectra for N-Ethhymethohcarbthio ligand and
acetylethTSC.
N-Ethhymethohcarbthio and acetylethTSC
The presence of singlets at 11.42 ppm and 10.59 ppm in the 1H NMR spectra of N-
Ethhymethohcarbthio and acetylethTSC, respectively, are labelled as g in figure 3A and as e
in figure 3B, respectively.[20] It is common for this signal to be used as a diagnostic test for
the identification of E and Z isomers.[6] According to Afrasiabi,[21] the chemical shift δ =
13–15 ppm proves that the ligand is in the E form, whereas δ = 9–12 ppm proves that the
ligand is in the Z form. Based on this analysis and coupled with the lack of a resonance
signal at ca. δ = 4.0 ppm which is attributed to a −SH proton resonance, it can be inferred
that both ligands exist as the Z isomer. An X-ray crystallographic study on acetylethTSC
confirms the existence of the thione moiety in the “free” ligand. We also believe that the
chemical shift of 13.2 ppm for acetylethTSC (see figure 3B) is due to equilibrium in solution
between the hydrogen-bonded (Z-conformation) and the non-hydrogen-bonded (E-
conformation) forms of acetylethTSC.
Oxidised products isolated from Compounds 1 and 3
It is important to determine the species that are formed when compounds 1 and 3 are
oxidised in DMSO. In order to determine such species, 1H NMR spectra were acquired on
the isolated oxidised products. All 1H NMR spectra exhibited broad signals (see Figures S21
and S22, Supporting Information). This phenomenon is attributed to the presence of some
residual paramagnetic vanadium(IV) species which could be due to vanadium(IV) species
which are in equilibrium with the vanadium(V) species that are formed upon aerial oxidation
in DMSO.
The 1H NMR spectrum of the oxidised product isolated from compound 1 exhibited
resonance signals that are due to aromatic protons in the region δ = 7.06 to 7.52 ppm.
The 1H NMR spectra of the oxidised products isolated from compounds 1 and 3 exhibited
resonance signals in the region δ = 7.82 to 8.09 ppm, and δ = 7.06 to 10.43 ppm,
respectively. These resonance signals are assigned to the proton of the azomethine group
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and the −NH proton of the indole ring of the L-tryptophan moiety, respectively. The
resonance signal corresponding to the N(2)-H proton of the N-Ethhymethohcarbthio ligand
in the oxidised product isolated from compound 3 are overlapped with the resonance signal
assigned to −NH proton of the indole ring of the L-tryptophan moiety.
Chemical shifts are observed at δ = 1.17 ppm and δ = 3.79 ppm, respectively, for the
oxidised product isolated from compound 3. These signals are assigned to the methylene and
methyl protons of the “free” N-Ethhymethohcarbthio ligand, respectively. Aromatic protons
are also observed as multiplets in the range δ = 6.87 to 6.96 ppm, and δ = 7.00 to 7.43 ppm.
ESI mass spectroscopy was used to prove the presence of DMSO-containing
vanadium(V)complexes, but 1H NMR spectroscopy has proven that chemical shifts for
DMSO occur at δ = 2.7 ppm and δ = 3.0-3.6 ppm, thus proving the existence of O-bonded
and S-bonded DMSO, respectively.[22] The absence of a peak at δ = 2.7 ppm implies the
absence of O-bonded DMSO.[22] The resonance due to the presence of an S-bonded DMSO
produces singlets at δ = 3.36 ppm and δ = 3.34 ppm for the oxidised products isolated from
compounds 1 and 3, respectively.
1H and 51V NMR studies on oxidised solutions of compounds 1-4 in DMSO-d6
It is interesting to note that over a 24 hour period, DMSO-d6 solutions of compounds 1–4
were found to be oxidised, with the eventual formation of vanadium(V) species. In such a
case, 51V NMR spectroscopy was used to definitively confirm the presence of vanadium(V)
species. Figure 4 shows the 51V NMR spectra for DMSO-d6 solutions of compounds 1–4
(10 mM) at room temperature; while table 5 shows the chemical shifts and percentages of
species for each vanadium(V) species. It is interesting that two species are formed on
oxidation of compounds 1, 2, and 4, while three species are formed for compound 3. It is
possible that a mononuclear species is formed in the range −480.5 to −467.7 ppm, based on
the chemical shifts obtained for 51V NMR spectra of vanadate(V) esters of monoionised and
diionised aromatic 1,2-diols as reported by Baruah et al.[23] For example, [VO(gsal)(HL1)],
[VO(asal)(HL1)], and [VO(vsal)(HL1)] (where gsal, asal, or vsal = diionised salicylaldimine
of L-glycine, L-alanine or L-valine; and HL1 = catecholate) have chemical shifts of −460,
−457, and −455 ppm, respectively, when DMSO-d6 was used as solvent.
It is interesting that Mauyra et al.[24] reported the synthesis of new oxidovanadium(V)
complexes, [VOL(hq)] by the reaction of [VO(acac)2] with ligands LH2 (where LH2 is the
dibasic tridentate ONO Mannich base [(S)-H2glysal, (S)-H2alasal, (S)-H2leusal and (S)-
H2ileusal; S represents the S-enantiomer] obtained by the reduction of the Schiff bases of
salicylaldehyde (sal) and the amino acids: glycine (gly), D,L-alanine (ala), leucine (leu) and
isoleucine (ileu), respectively) in the presence of 8-hydroxyquinoline (Hhq). Spectral studies
were used to confirm an octahedral structure for the complexes.[24] The complexes exhibited
a single 51V NMR signals (with DMSO-d6 as solvent) in the range −464.6 to −468.0 ppm
due to the existence of a single isomeric species in solution.[24] Due to the similar chemical
shifts of the species in the range −480.46 to −467.69 ppm, we can conclude that a
mononuclear vanadium(V) species is formed when the respective vanadium(IV) complexes
are oxidised in DMSO-d6. The reason why the vanadium(V) species (which is formed from
compound 3) has a chemical shift of −467.7 ppm, is yet to be determined.
Mauyra et al.[24] carried out a time dependent 51V NMR spectroscopic study (in DMF-d7
and CD3OD) in order to investigate the possible isomerisation and/or further reaction in
solution. Freshly prepared solutions of [VO(S-alasal)(hq)] showed a signal at −466.7 ppm.
As time elapsed, a second, broader signal at −516.3 ppm was formed, which had about the
same integral intensity as the −466.7 ppm signal after three days, and about twice its
intensity after one week. The authors concluded that the change in chemical shift was too
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large to represent diastereomers based on pairs of enantiomers, and therefore, assigned the
new signal to a [VO2] or [(VO)2μ-O] species, i.e., the oxygenated product after a slow loss
of 8-hydroxyquinoline. They also concluded that as generation of a [(VO)2μ-O] species
usually dominates during oxygenation[24] in the absence of a base, the signal at −516.3 ppm
is most probably due to the [(VO)2μ-O] species. In our case, the chemical shift of
approximately −541 ppm accounts for the major species formed for compounds 1–4. We
believe that this is the [V2O3(Sal-L-tryp)2(DMSO)2]. This species was also detected by ESI
MS (m/z = 918.3, [[V2O3(Sal-L-tryp)2(DMSO)2] + H]+) from oxidised DMSO solutions of
compounds 1 and 3. A similar complex with N-salicylidene-L-alaninate (sal-L-ala) as
ligand, viz., [V2O3(sal-L-ala)2].2CH2Cl2, was also reported by Nakajima et al.[25]
We believe that [VO(Sal-L-tryp)(DMSO-d6)(OH)] is formed as an intermediate when
compounds 2 and 4 are oxidised in DMSO-d6, all within experimental errors in the
determination of the percentage species. We believe that the species that has a chemical shift
at -559.3 ppm is mononuclear, and are proposing its structure as shown in Scheme 1. We
propose its formula as [VO(sal-L-tryp)(DMSO)(N-Ethhymethohcarbthio)]. Based on 51V
NMR spectroscopy, we propose the existence of equilibrium between mononuclear and
binuclear vanadium(V) species (see Scheme 1).
Based on 1H NMR spectroscopic studies (See Figures S27-S30, Supporting Information), it
appears as if the thiosemicarbazone ligands are now “free” when compounds 2-4 are
oxidised in DMSO-d6 and DMSO. The 1H NMR chemical shifts of the “free” ligands are
within the values shown in figures 3, and those chemical shifts obtained for MeATSC as
reported by Beckford et al.[6] ESI MS have also proven the existence of a “free”
thiosemicarbazone ligand for a mixture that resulted from the oxidation of compound 3 in
DMSO. In this study, a m/z ratio of 252.3 accounts for the presence of the “free” ligand, N-
Ethhymethohcarbthio.
UV-visible and fluorescence spectroscopic studies of compound 1-4
UV-visible spectra were acquired for compounds 1-4 in DMSO (see Figures S31-S34,
Supporting Information for the data). Assignments of the absorption bands are shown in
Table 6. Charge transfer bands in the region 266-292 nm which can be assigned to π→π*
transitions associated with the thioamide moiety are observed for compounds 2–4.[18a, 26]
These occurred at 266 nm and 292 nm (shoulder) for compound 2, 270 nm and 288 nm
(both as shoulders) for compound 3, and 276 nm for compound 4, respectively. Charge
transfer bands assigned to n→π* transitions of aromatic rings are observed in the region
316-352 nm.[18a, 19a, 26-27] These are observed as a shoulder at 316 nm for compound 2, at
330 nm for compound 3, and 352 nm for compound 4, respectively.
In the UV region, oxidovanadium(IV) complexes derived from salicylaldehyde generally
possess a low-energy band around 375 nm which can be attributed to a π→π* transition
originating mainly from the azomethine chromophore.[11] This occurs at 388 nm for
compound 2, as a shoulder at 390 nm for compound 3, and hidden under the n→π*
transitions at 352 nm for compound 4. A band in the region 550-558 nm is assigned to
LMCT transitions of the type p→d where p and d represent phenolato oxygen’s lone pair
and vanadium 3d orbitals, respectively.[28] This occurs at 558 nm for compound 1, 550 nm
for compound 2, and 558 nm for compound 4. A similar band is absent for compound 3
since it is believed to be hidden under the band at 614 nm which is assigned as d→d
transitions.
Bands assigned to d-d transitions were also observed in the region 756-758 nm for
compounds 1, 2 and 4.[19b] This occurred at 758 nm for compound 1 and 756 nm for
compounds 2 and 4. In the electronic spectra of compounds 2 and 4, bands at 592 nm for
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compound 2 and 590 nm for compound 4 are also assigned to d→d transitions, appearing as
shoulders of the much stronger LMCT band in the region 550-558 nm.[19b]
Fluorescence spectra were acquired for compounds 2–4 in DMSO (See Figures S35-S37,
Supporting Information). The excitation wavelengths for compounds 2, 3, and 4, were 400,
330, and 340 nm, respectively. Compound 2 which contains an anthracene unit in MeATSC
produced the highest intensity in its fluorescence spectra; while compounds 3 and 4
produced the lower intensities.
ESR spectroscopy
Compounds 1–4 were also characterised by low-temperature ESR spectroscopy, where at 10
K, each complex exhibits a powder type axial g = 2 ESR signal (S = ½) with a minor
rhombic distortion. The observed hyperfine structure shows sixteen line ESR signals with
partial overlapping on three lines. Figure 5 shows two representative ESR spectra along with
simulations for compounds 1 and 4. These spectra are characteristic of slowly tumbling
macromolecular complexes consistent with vanadyl (VO2+)-containing complexes,
indicating that the freshly prepared vanadium metal centre has a +4 oxidation state for the
two complexes. The anisotropic sixteen line powder ESR spectra are due to the hyperfine
interaction between the electron spin and the nuclear spin of 51V(IV) (I = 7/2, 100% natural
abundance).
The powder ESR spectra of compounds 1–4 were simulated to determine the magnitudes of
the principal 51V hyperfine coupling constants (Axx, Axx, and Azz) and g values using the
ESR simulation program DOUBLET.EXE.[29] The ESR parameters obtained from spectral
simulations are shown in Table 7. The large A values and broader linewidth are presumably
due to the sulphur ligation and hexacoordination geometry. The vanadyl cation, VO2+, is
known to form complexes that are pentacoordinate or square bipyramidal with a short V=O
bond.[30] However, hexacoordinate vanadyl-containing complexes with mixed N/O/S
ligands are thus poorly characterised so far. The ESR spectra of the complexes described
here may be useful in future comparison studies of VO2+ in complexes and biological
systems. Nevertheless, these ESR results are in agreement with those of UV-visible and FT
IR spectral measurements, and thus prove that each synthesised compound has a
vanadium(IV) metal centre prior to air oxidation of the DMSO solution. On another note, we
plan to carry out future studies involving DFT calculations in order to elucidate the
dependence of calculated 51V Az values on the orientation and geometry of coordinated
thiosemicarbazone and water ligands in compounds 1–4. Such a study involving calculated
and experimental Az values for compounds 1–4 would complement the excellent piece of
data for VIVO complexes as reported by Garriba and co-workers.[31]
Pharmacology
In vitro cytotoxicity—The objective of this research is to evaluate the anti-proliferative
activity of compounds 2–4 against colon cancer cell lines (HTC-116, Caco-2 and HT-29),
and to compare the anti-proliferative activity on one non-cancerous colon cell line
(CCD-18Co). Compounds 2–4, cisplatin, and etoposide were evaluated for their cytotoxicity
on three different cancer colon cell lines (HCT-116, Caco-2 and HT-29) by means of a
colorimetric assay (MTS assay) which measures mitochondrial dehydrogenase activity as an
indication of cell viability. The effects of the compounds on the viability of these cells were
evaluated after continuous incubation (24, 48, and 72 hours).
As such, the growth inhibition effects of compounds were investigated in non-cancerous
colonic myofibroblasts CCD-18Co cells and compared to cancer colon cell lines. The results
demonstrated the greatest difference in the inhibition of cell proliferation between cancer
Lewis et al. Page 8
Eur J Inorg Chem. Author manuscript; available in PMC 2013 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
lines and the non-cancerous CCD-18Co cells. Compounds 2–4 have been shown to time-
dependently decrease cell viability of HCT-116, Caco-2 and more potently in HT-29 cells
(Table 8). Compound 4 was the most active of the three tested; while compounds 2 and 3
showed similar activities in both cancer cell lines. Figure 6 shows a plot of percentage cell
viability versus concentration of compound 4 against the HT-29 cancer cell line; while table
8 shows the IC50 values for inhibition of cell proliferation for compounds 2–4, with IC50
values generally around 100 μM concentration at 72 hours in compounds 2 and 3. None of
the compounds had better efficacy against any of the cancer cell lines when compared to the
standard, etoposide. It is very important to note that compound 4 has a better efficacy
against the HT-29 cancer cell line when compared to the standard, cisplatin (Table 8).
Compounds 2–4 exhibited less inhibitory effects in human normal CCD-18Co cells,
indicating a possible cytotoxic selectivity towards colon cancer cells (Table 8). IC50 values
in CCD-18Co were around 3-fold and 2-fold than HT-29 and Caco-2 and HCT-116,
respectively. However, cytotoxic selectivity towards cancer colon cells of cisplatin (as a
positive control) was slightly lower, except on Caco-2 cells (Table 8). These results are also
in good agreement with those of a previous study where it was shown that cisplatin inhibited
cell proliferation by about 70% in both cell lines (cancer and normal colon cells).[32] In
general, compounds 2–4 which have been proven to be growth suppressors of cancer cells,
but do not affect non-cancerous cells, may have a potential in chemotherapy.
Although metal complexes are being investigated as probes and therapeutics, there are a
relatively few studies on their mechanism of uptake. It has been found that metal complexes
that are lipophilic cations may passively diffuse across the plasma membrane in response to
the membrane potential.[33] A ruthenium(II) complex containing the lipophilic 4,7-
diphenyl-1,10-phenanthroline ligand has been shown to enter the membrane by passive
diffusion in a membrane-potential dependent manner.[33] It is believed that the excellent
efficacy of the ruthenium(II) complexes with thiosemicarbazones as reported in a study by
Beckford and co-workers,[6] is likely due to the fact that those complexes are lipophilic
cations. As a point of speculation, this may explain why cations such as [(bpy)2Ru(TSC)]2+
and [(phen)2Ru(TSC)]2+ (where TSC = 9-anthraldehydethiosemicarbazones),[6] have better
efficacies against HT-29 and HCT-116 cell lines versus our neutral vanadium(IV)
complexes. Based on 1H NMR spectroscopy and ESI MS studies, where the “free” ligand
was observed, we believe that the “free” ligand is likely causing the cell death as apposed to
the vanadium species in the media. In order to prove this belief, in the near future, we will
have to carry out in vitro studies with the “free” ligands. A systematic study will have to be
carried out with the ruthenium(II) complexes and compounds 2–4, all under the same
conditions. Apart from such a study, in the future, a more detailed emphasis will be placed
on the methods used to examine cellular accumulations to identify the mechanism(s) of
uptake, and to monitor possible efflux of compounds 2–4, and their analogues.
Conclusions
Two novel thiosemicarbazone and three novel vanadium(IV) complexes with mixed-ligands
were successfully synthesised and characterised. Anti-cancer properties of compounds 2–4
were examined with three colon cancer cell lines, HTC-116, Caco-2, and HT-29, along with
a comparative anti-proliferative study on non-cancerous colonic myofibroblasts, CCD-18Co.
Compounds 2 and 3 exhibited a less inhibitory effects in human non-cancerous CCD-18Co
cells, indicating a possible cytotoxic selectivity towards colon cancer cells. In general, those
compounds which exhibited anti-proliferative activity on cancer cells, but did not affect non-
cancerous colorectal cells, may have a potential in chemotherapy.
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Experimental Section
Materials and methods
Analytical or reagent grade chemicals were used throughout this study. All the chemicals
including solvents were obtained from Sigma-Aldrich (St. Louis, MO, USA) or other
commercial vendors, and used as received. Microanalyses (C, H, N) were performed by
Desert Analytics, Tucson, U.S.A. and Columbia Analytical Services 3860 S. Palo Verde
Road Suite 303 Tucson, AZ 85714, U.S.A. 1H and 13C NMR spectra were acquired in
DMSO-d6 on a JEOL ECX-300, a Varian 300 MHz, Bruker 400 MHz, or a Varian 500 MHz
spectrometer operating at room temperature. The residual 1H and 13C present in DMSO-d6
(2.49 and 39.7 ppm, respectively) were used as internal references. 51V NMR spectra were
acquired on a Varian 500 MHz spectrometer with DMSO-d6 as solvent and VOCl3 as an
external reference as described for vanadium(V) compounds.[34]
ESR spectra were acquired at either 10 or 20 K on a Bruker ER200D spectrometer using a
4116DM resonator. Sample temperature was maintained with a temperature controller
(ITC503S), an ESR910 liquid helium cryostat and LLT650/13 liquid helium transfer tube
(Oxford Instruments, Concord, MA, U.S.A.) spectrometer. Instrument conditions were as
follows: modulation frequency = 100 kHz, modulation amplitude = 0.3 G, microwave
frequency = 9.64 GHz, and microwave power = 0.004 mW.
FT IR spectra were acquired in the range 4000-400 cm-1 using the ATR accessory (with a
diamond crystal) on a Nicolet 6700 FTIR spectrophotometer. Electronic spectra were
acquired using quartz cuvettes on a HP8452 diode array spectrophotometer using DMSO as
the solvent. Fluorescence spectra were acquired on a Cary Eclipse fluorescence
spectrophotometer (Varian Inc.) using a slit width of 10 nm. ESI MS data was acquired on
an HP Agilent 1956b single-quadrupole mass spectrometer. Samples were dissolved in an
acetic acid/methanol mixture; then the solution was introduced by direct injection using a
syringe pump with a flow rate of 100 μL s-1, while sweeping the cone voltage from 0 to 200
V at a rate of 10 V min-1. All m/z ratios and percentages presented as ESI MS data were
determined by using the MestReNova software.
X-ray crystallography
Crystallographic data were collected at T = 90 K on Bruker Kappa Apex-II CCD
diffractometer equipped with CuKα radiation and an Oxford Cryosystems Cryostream
cooler. The structure of acetylethTSC was solved using SHELXS,[35] and refined using the
SHELX97[36] software packages. All H atoms were visible in difference maps. Coordinates
of the NH hydrogen atoms were refined individually, while those on C were placed in
idealized positions, with torsional parameters refined for the methyl groups. Crystal data:
C8H12N4S2, FW = 228.34, monoclinic, space group = C2/c, a =10.4549(10), b =
10.8970(10), c = 18.7694(15) Å, β = 91.544(5)°, V = 2137.6(3) Å3, Z = 8, T = 90.0(5)K, μ
= 4.25 mm-1, dcalc = 1.419 g cm−3, colourless parallelepiped, dimensions = 0.18 × 0.17 ×
0.09 mm, reflections collected = 8017, unique reflections = 1901, observed reflections (I >
2σ(I)) = 1738, Rint = 0.026, no. of parameters = 136, R1 = 0.028, wR2 = 0.069, GOF(F2) =
1.065, CCDC No. = 812348.
Synthesis of ligands
9-Anthraldehydethiosemicarbazone (ATSC), 9-anthraldehyde-N(4)-
methylthiosemicarbazone (MeATSC) was prepared according to the procedure as by
Beckford et al.[6]
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Synthesis of N-Ethhymethohcarbthio
o-Vanillin (3.00 g, 19.7 mmol) and 4-ethyl-3-thiosemicarbazide (2.35 g, 19.7 mmol) were
placed in a 250 ml round bottom flask, followed by absolute ethanol (100 ml).
Approximately 10 drops of glacial acetic acid were added to the off-white suspension, and
the reaction mixture was refluxed for three hours. The reaction mixture was then cooled to
room temperature and filtered through a sintered glass crucible. The white residue was
washed with ethanol (3 × 15 ml), followed by ether (3 ×10 ml) and allowed to air dry. Yield
= 4.97 g (99%). The purity was checked by elemental analysis. Calc. for C10H13N3O2S: C,
52.15; H, 5.97; N, 16.59. Found: C, 52.53; H, 6.16; N, 17.02; Infrared spectrum (ν/cm-1):
FT IR (ν/cm-1): 3304 (m) (-N1H), 3300 (m) (-N2H), 3130 (br) (OH), 1155 (m) (N-N), 1606
(m) (TSC (C=N)), (1267) (m) and (831) (m) (C=S). 1H NMR (400 MHz; DMSO-d6); δH =
1.15 (t, Jt = 7.10 Hz, 3H, -CH3), 3.46 (s, 1H, -CH3-OAr), 3.60 (q, 2H, CH2), 3.80 (s, 1H,
(azomethine -CH=N)), 6.79 (t, Jt = 7.95 Hz, CHar), 6.96 (dd, Jdd = 1.49 and 8.06 Hz, CHar),
7.55 (dd, Jdd = 1.51 and 7.93 Hz, CHar), 8.40 (s, H, aminic NH)), 11.41 (s, 1H, ArOH)), and
11.42 ppm (s, 1H, hydrazinic-NH)). 13C (400 MHz; DMSO-d6); δ = 176.86 (C=S), 147.86
(CH=N), 145.88 (-COCH3ar), 139.00 (PhOH), 120.82 (CCH=Nar), 118.91 (CHar), 118.10
(CHar), 112.66 (CHar), 58.85 (OCH3), 38.28 (CH2), 14.60 (CH3).
Synthesis of acetylethTSC
2-Acetylthiazole (0.636 g, 0.518 ml 5.0 mmol) was placed in a 100 ml round bottom flask,
followed by anhydrous methanol (25 ml). 4-Ethyl-3-thiocarbazide (0.596 g, 5.0 mmol) in
anhydrous methanol (25 ml) was slowly added to the solution of 2-acetylthiazole, followed
by a few drops of concentrated hydrochloric acid were added. The reaction mixture was
refluxed with stirring for two hours and then evaporated to a minimum volume to form a
yellow solid. The mixture was filtered, and the residue was washed with ether and air-dried.
Yield = 0.750 g (66%). A single crystal for X-ray crystallography was grown by slow
evaporation from methanol. FT IR (ν/cm-1): 3164 (m) (-N1H), 3054 (m) (-N2H), 1059 (m)
(N-N), 1543 (m) (TSC (C=N)), (1296) (m) and (813) (m) (C=S). 1H NMR (400 MHz;
DMSO-d6); δH = 1.16 (t, Jt = 7.10 Hz, 3H, -CH3), 2.42 (s, 3H, CH3CH=N), 3.61 (d, 2H,
CH2), 7.79 (d, Jd = 3.21 Hz, CHar), 7.88 (d, Jd = 3.19 Hz, CHar), 8.08 (d, Jd = 3.24 Hz,
CHar), 8.30 (s, H, aminic NH), 10.58 (s, 1H, hydrazinic-NH), and 13.2 (s, H-bonded
hydrazinic-NH) ppm.
Synthesis of the reduced Schiff base (2-(2-hydroxybenzylamino)-3-(1H-indol-3-
yl)propanoic acid)
The reduced Schiff base was prepared using a known procedure involving salicylaldehyde,
amino acids, and NaBH4, but with L-tryptophan using the following synthetic procedure:[10]
L-tryptophan (2.04 g, 10.0 mmol) and potassium hydroxide (0.56 g, 10.0 mmol) were added
to a 125 ml Erlenmeyer flask, followed by deionised water (10 ml). Salicylaldehyde (1.029
ml, 10.0 mmol) in absolute ethanol (10 mL) was slowly added to the mixture. The yellow
solution was stirred for thirty minutes prior to cooling in an ice bath.
The intermediate Schiff base which was produced in situ was reduced with an excess of
sodium borohydride (0.46 g, 12 mmol) in water (5 ml) containing 10 drops of 2 M sodium
hydroxide. The solution was stirred for ten minutes, and the yellow colour was slowly
discharged. The solution was then acidified with concentrated HCl to pH 4.68. The resulting
solid was filtered off, washed with ethanol (2 × 30 ml) and diethyl ether (2 × 30 ml) and
dried. The white solid obtained was recrystalized twice from water/ethanol(1:1). Yield =
1.08 g (35%). m/z (ESI) (+ve mode) 311.08 (100.00%, [M + H]+), 242.42 (13.04%, [M −
CHO3 + H]+), 620.36 (12.77%, [2M + H]+), 930.39 (5.02%, [3M + H]+), 1240.92 (3.92%,
[4M + H]+). FT IR (ν/cm-1): 3392 (m) (indolic NH), 3055 (br) (OH), 1208 (m) (C-O)), 1494
(m) (COOs) and 1592 (m) (COOas). 1H NMR (400 MHz; DMSO-d6); δH = 2.67 (d, 2H),
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3.21 (d, 2H), 3.05 (d, 2H), 5.91 (t, 1H), 6.15 (d, 1H), 6.31 (d, 1H), 6.62 (m, 1H), 6.62 (m,
1H), 6.62 (m, 1H), 6.62 (m, 1H,), 6.90 (d, 1H) and 7.18 ppm (d, 1H). 13C (400 MHz;
DMSO-d6); δ = 28.57, 46.72, 63.61, 110.66, 111.57, 113.46, 118.50, 118.69, 121.37,
123.85, 123.89, 126.95, 127.78, 128.16, 128.34, 135.97, 164.55, and 182.05 ppm.
Synthesis of K[(Sal-L-tryp)]
This complex was prepared using an analogous synthesis as reported by Vanco et al.[37] To
a mixture of L-tryptophan (3.07 g, 15.0 mmol) and potassium hydroxide (0.85 g, 15.0
mmol) dissolved in water (5 ml), the solution of salicylaldehyde (1.57 ml, 15.0 mmol) in
ethanol (10 ml) was added with stirring. The resulting yellow solution was stirred at room
temperature for 24 hours; then the solution was diluted by ethanol (25 ml). Upon slow
evaporation of solvent, a yellow oil was formed which was then triturated with diethyl ether.
The mixture was then filtered to give a yellow powder which was dried under vacuum.
Yield = 4.85 g (93%). m/z (ESI) (+ve mode) 344.05 (39.65%, [M + H]+), 300.03 (100.00%,
[M − OH − K + H]+), 281.14 (46.08%, [M − OH − O − K + H]+), 262.12 (1.51%, [M −
COO − K + H]+), 242.62 (64.65%, [M − COO − OH − K + H]+) and 205.20 (50.43%, [M −
C7H6O − K + H]+). FT IR (ν/cm-1): 3407 (m) (indolic NH), 3169 (br) (OH), 1194 (m) (C-
O)), 1521 (m) (COOs), 1604 (m) (COOas) and 1570 (m) (TSC (C=N)). 1H NMR (400 MHz;
DMSO-d6); δH = 3.13 (dd, Jdd = 8.9 and 16 Hz, 2H), 3.49 (s, 1H), 4.07 (s, 1H), 6.59 (s, 1H),
6.72 - 7.06 (m, 1H), 6.72 - 7.06 (m, 1H), 7.20 (s, 1H), 7.20 (m, 1H), 7.20 (m, 1H), 7.20 (m,
1H), 7.35 - 7.58 (m, H), 7.35 - 7.58 (m, 1H), and 11.17 (s, 1H) ppm. 13C (400 MHz; DMSO-
d6); δ = 30.16, 64.82, 72.43, 111.39, 111.56, 115.74, 117.62, 117.99, 118.31, 118.33,
120.59, 123.38, 127.36, 131.77, 132.01, 163.27, and 172.88 ppm.
Synthesis of [VO(Sal-L-tryp)(H2O)] 1
This complex was prepared as by Costa Pessoa et al.[11] L-tryptophan (1.14 g, 5.60 mmol)
and sodium acetate trihydrate (1.47 g, 10.8 mmol) were placed in a 250 ml round bottomed
flask with deionized water (100 ml). The mixture was stirred and heated at 50 °C to
completely dissolve the L-tryptophan. Salicylaldehyde (0.59 ml, 5.6 mmol) in absolute
ethanol (14 ml) was slowly added to the mixture. The resulting yellow solution was stirred
vigorously on a magnetic stirrer and an aqueous solution of VOSO4.×H2O (0.78 g, 4.8
mmol) in water (2 ml) was added dropwise to the solution. The solution was stirred for 30
minutes. A deep dark brown precipitate formed and the resulting solution was then filtered
under vacuum. The grey solid formed was washed with water (30 ml) followed by a ethanol-
water mixture (50:50) (30 ml) and air-dried. Yield = 1.19 g (63%). Calc. for C18H16N2O5V:
C, 55.25; H, 4.12; N, 7.16. Found: C, 55.16; H, 4.31; N, 6.87 (lit.[11] Calc. for
C18H16N2O5V: C, 55.25; H, 4.12; N, 7.16. Found: C, 55.2; H, 4.2; N, 7.1). FT IR (ν/cm-1):
3478 (m) (indolic NH), 3014 (br) (OH), 1540 (m) (C-O), 1490 (m) (COOs), 1597 (m)
(COOas), 1600 (m) ([(Sal-L-tryp)] C=N), and 997 (s) (V=O) (lit.[11] 3480 (m) (indolic NH),
3065 (br) (OH), 1630 (m) ([(Sal-L-tryp)] (C=N)), 1600 (m) (C-O)) and 970 (s) (V=O)). UV-
visible spectrum (MeOH), λmax./nm (ε/M-1 cm-1): 558 (44) and 758 (27); (lit.:[11] UV-
visible spectrum (DMSO), λmax./nm (ε/M-1 cm-1): 275 (15400) and 375 (4850), 520 (45),
and 730 (20)).
Synthesis of [VO(Sal-L-tryp)(MeATSC)].1.5 C2H5OH 2
(E)-2-(Anthracen-9-ylmethylene)-N-methylhydrazinecarbothioamide (0.15 g, 0.51 mmol)
and [VO(Sal-L-tryp)(H2O)] (0.20 g, 0.51 mmol) were placed in a dried 250 ml round bottom
flask. Absolute ethanol (100 ml) was added to the flask and the solution was refluxed with
stirring under argon for two hours in an oil bath at 110 °C. The orange-blue solution which
was produced was then rotaryevaporated to dryness. Diethyl ether was added to the product
and the mixture was filtered under vacuum, and the green residue was collected and air-
dried. Yield = 0.23 g (68%). Calc. for C38H38N5O5.5SV: C, 62.03; H, 5.21; N, 9.52. Found:
Lewis et al. Page 12
Eur J Inorg Chem. Author manuscript; available in PMC 2013 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
C, 62.62; H, 5.25; N, 9.33. m/z (ESI) 666.17 (100.00%, [M + H]+), 577.08 (33.10%, [[M −
C2H5N2S] + H]+, 405.14 (31.86%, [[M − C17H17N3] + H]+), 292.14 (54.60%, [MeATSC +
H]+). FT IR (ν/cm-1): 3308 (m) (indolic NH), 3340 (m) (-N1H), 2976 (m) (-N2H), 1148 (m)
(N-N), 1544 (m) (C-O)), 1491 (m) (COOs), 1600 (s) (COOas), 1624 (m) (TSC (C=N)), 1590
(m) ([(Sal-L-tryp)] (C=N)), (1225) (m), (829) (m) (C=S), (455) (m) (V-S), and 980 (s)
(V=O). UV-visible spectrum (DMSO), λmax./nm (ε/M-1cm-1): 226 (74835), 292 (sh)
(17954), 316 (sh) (10046), 388 (15013), 550 (54), 592 (sh) (45), and 756 (28).
Synthesis of [VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O 3
This was prepared in a similar manner to 2 using (E)-2-(4-hydroxy-3-methoxybenzylidene)-
N methylhydrazinecarbothioamide (0.065 g, 0.26 mmol) and [VO(Sal-L-tryp)(H2O)] (0.10
g, 0.26 mmol). Yield = 0.12 g (78%). Calc. for C29H30N4O7 SV: C, 53.33; H, 4.64; N,
11.11. Found: C, 53.18; H, 5.21; N, 11.09. m/z (ESI) 624.87 (100.00%, [M − H]-), 431.90
(64.75%, [M − C11H10N2O − H]-), 407.85 (20.99%, [M − C11H15N3O2S - H]-), 287.88
(12.70%, [[C11H15N3O2S − C8H7N] - H]-), 252.00 (25.74%, [N-Ethhymethohcarbthio -
H]-). FT IR (ν/cm-1): 3210 (m) (indolic NH), 3306 (m) (-N1H), 2970 (m) (-N2H), 3010 (br)
(OH), 1154 (m) (N-N), 1540 (m) (C-O)), 1480 (m) (COOs), 1600 (s) (COOas), 1620 (m)
(TSC (C=N)), 1580 (m) ([(Sal-L-tryp)] (C=N)), (1270) (m), (802) (m) (C=S), (454) (m) (V-
S) and 976 (s) (V=O). UV-visible spectrum (DMSO), λmax./nm (ε/M-1cm-1): 270 (sh)
(10984), 288 (sh) (13874), 330 (24837), 390 (sh) (18250), and 620 (852).
Synthesis of [VO(Sal-L-tryp)(acetylethTSC)].C2H5OH 4
This was prepared in a similar manner to compound 2 using 2-acetylthiozole-4,4’-
dimethylthiosemicarbazone (0.12 g, 0.51 mmol) and [VO(Sal-L-tryp)(H2O)] (0.20 g, 0.51
mmol). Yield = 0.18 g (57%). Calc. for C28H32N6O5S2V: C, 51.93; H, 4.98; N, 12.98.
Found: C, 52.49; H, 4.72; N, 10.91. m/z (ESI) 600.25 (2.71%, [M + H]+), 513.57 (100.00%,
[M − C3H7NS + H]+), 482.38 (37.11%, [M − C7H5NO] + H]+), and 336.06 (4.13%, [[M −
C17H15N2O] + H]+). FT IR (ν/cm-1): 3229 (m) (indolic NH), 3310 (m) (-N1H), 2976 (m) (-
N2H), 1149 (m) (N-N), 1545 (m) (C-O)), 1480 (m) (COOs), 1600 (s) (COOas), 1624 (m)
(TSC (C=N)), 1580 (m) ([(Sal-L-tryp)] (C=N)), (1287) (m), (819) (m) (C=S), (455) (m) (V-
S) and 982 (V=O). UV-visible spectrum (DMSO), λmax./nm (ε/M-1cm-1): 276 (21969), 352
(14227), 558 (80), 590 (sh) (70), and 756 (38).
Oxidation of compounds 1 and 3 in DMSO
[VO(Sal-L-tryp)(H2O)] 1 (0.1 g, 0.26 mmol) was added to an evaporating dish.
Dimethylsulfoxide (10 ml) was added and the resulting solution was left to evaporate for 32
days to leave a solid. Yield = 0.09 g. m/z (ESI) (+ve mode) 468.60 (1.67%, [M + H]+),
242.41 (100.00%, [M − OH − DMSO − C8H7N + H]+), 451.05 (48.25%, [M − OH + H]+),
763.68 (30.06%, [[V2O3(Sal-L-tryp)2] + H]+), 776.77 (49.36%, [[V2O3(Sal-L-tryp)2(H2O)]
+ H]+) and 918.28 (3.13%, [[V2O3(Sal-L-tryp)2(DMSO)2] + H]+). FT IR (ν/cm-1): 3185 (m)
(indolic NH), 3194 (br)(OH), 1551 (m) (C-O)), 1497 (m) (COOs), 1618 (s) (COOas), 1667
(m) (TSC (C=N)), 1581 (m) ([(Sal-L-tryp)] (C=N)), 1164 (m), 1213 (m) (S=O), 949 (s)
(V=O). 1H NMR (400 MHz; DMSO-d6); δH = 2.52 (d, 3H), 2.52 (d, 3H), 10.89 (s, 1H, 7.06
(s, 1H), 7.22 (m, 1H), 7.22 (m, 1H), 7.52 (d, 1H, 8.06 (d, 2H), 3.36 (s, 1H), 3.00 (s, 2H),
7.22 (m, 1H), 7.22 (m, 1H), 7.22 (m, 1H), 7.22 (m, 1H), 9.93 (s, 1H), and 7.06 ppm (s, 1H).
[VO(Sal-L-tryp)(N-Ethhymethohcarbthio)].H2O 3 (0.1 g, 0.16 mmol) was oxidised in an
analogous manner. Yield = 0.09 g. m/z (ESI) (+ve mode) 470.01 (0.50%, [M + H]+), 252.26
(100.00%, [N-Ethhymethohcarbthio + H]+), 451.96 (2.97%, [M − OH + H]+), 702.75
(2.15%, [M − OH + N-Ethhymethohcarbthio + H]+), 763.22 (0.74%, [[V2O3(Sal-L-tryp)2 +
H]+), 775.40 (1.08%, [[V2O3(Sal-L-tryp)2(H2O)] + H]+) and 916.44 (0.75%, [[V2O3(Sal-L-
tryp)2(DMSO)2] + H]+). FT IR (ν/cm-1): 3193 (br)(OH), 1666 (m) (C=N), 1600 (C=O),
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1550 (m) (C-O)), 1133 (m), 1157 (m) (S=O), 946 (s) (V=O). 1H NMR (400 MHz; DMSO-
d6); δH = 2.52 (d, 3H), 2.52 (d, 3H), 10.43 (s, 1H), 6.96 (s, 1H), 7.22 (m, 1H), 7.22 (m, 1H),
7.42 (d, 1H), 8.00 (d, 2H), 3.34 (s, 1H), 3.00 (s, 2H), 7.22 (m, 1H), 7.22 (m, 1H), 7.22 (m,
1H), 7.22 (m, 1H), 9.95 (s, 1H), and 6.96 ppm (s, 1H).
Pharmacology
Cell culture—Three human colon cancer cells, HT-29 (human colon adenocarcinoma),
HCT-116 (human colon carcinoma) and Caco-2 (human epithelial colorectal
adenocarcinoma)_as well as non-cancerous human colon cells, CCD-18Co (human colon
fibroblasts) were used in this study. All cell lines were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, U.S.A.) and maintained at the University of
Rhode Island, U.S.A. Caco-2 cells were grown in EMEM medium supplemented with 10%
v/v fetal bovine serum, 1% v/v non-essential amino acids, 1% v/v L-glutamine and 1% v/v
antibiotic solution (Sigma-Aldrich). HT-29 and HCT-116 cells were grown in McCoy’s 5a
medium supplemented with 10% v/v fetal bovine serum, 1% v/v non-essential amino acids,
2% v/v HEPES and 1% v/v antibiotic solution. CCD-18Co cells were grown in EMEM
medium supplemented with 10% v/v fetal bovine serum, 1% v/v non-essential amino acids,
1% v/v L-glutamine and 1% v/v antibiotic solution and were used from PDL = 26 to PDL =
35 for all experiments. Cells were maintained at 37 °C in an incubator under a 5% CO2/95%
air atmosphere at constant humidity and maintained in the linear phase of growth. The pH of
the culture medium was determined using pH indicator paper (pHydrionTM Brilliant, pH
5.5-9.0, Micro Essential Laboratory, NY, U.S.A.) inside the incubator. All test samples were
dissolved in DMSO (<0.5 % in the culture medium) by sonication; then filter sterilised (0.2
μm) prior to addition to the culture media. Control cells were also carried out in parallel
sequences, and subjected to the same changes in medium with a 0.5 % DMSO.
Cytotoxicity assay—This assay was carried out as described previously[38] in order to
measure the IC50 values for samples. Briefly, the in vitro cytotoxicity of samples were
assessed in tumour cells by a tetrazolium-based colorimetric assay, which takes advantage of
the metabolic conversion of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium, inner salt] to a reduced form that
absorbs light at 490 nm. Cells were counted using a hemacytometer and were plated at
2000-5,000 cells per well, depending on the cell line, in a 96-well format for 24 hours prior
to drug addition. Test samples and a positive control, etoposide 4 mg ml-1 (Sigma-Aldrich),
were dissolved in DMSO by sonication. All samples were diluted with media to the desired
treatment concentration and the final DMSO concentration per well did not exceed 0.5%.
Control wells were also included on all plates. Following a 24, 48, or 72 hour drug-
incubation period at 37 °C with serially diluted test compounds, MTS, in combination with
the electron coupling agent, phenazine methosulphate, was added to the wells and cells were
incubated at 37 °C in a humidified incubator for three hours. Absorbances at 490 nm
(OD490) were acquired on a spectrophotometer (SpectraMax M2, Molecular Devices Corp.,
operated by SoftmaxPro v.4.6 software, Sunnyvale, CA, U.S.A.) to obtain the number of
surviving cells relative to control populations. The results are expressed as the median
cytotoxic concentrations (IC50 values) and were calculated from six-point dose response
curves using 4-fold serial dilutions. Each point on the curve was tested in.
Statistics
Data are expressed as mean ± SE for three replications on each cell line.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
A thermal ellipsoid plot (50% probability envelopes) for acetylethTSC.
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Figure 2.
Hydrogen bonding in acetylethTSC.
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Figure 3.
1H NMR spectra of N-ethhymethohcarbthio and acetylethTSC in DMSO-d6.
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Figure 4.
51V NMR spectra of compounds 1–4 after being oxidised in DMSO-d6 for 24 hours.
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Figure 5.
X-band continuous-wave ESR spectra of [VO(Sal-L-tryp) (H2O)] [compound 1 (A), 10 mM
in DMSO] and [VO(Sal-L-tryp)(acetylethTSC)].C2H5OH [compound 4 (B), 10 mM in
DMSO] overlaid with spectral simulations on top of the original data. Instrument conditions
were as follows: temperature = 10 K, modulation frequency = 100 kHz, modulation
amplitude = 0.3 G, microwave frequency = 9.64 GHz, and microwave power = 0.004 mW.
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Figure 6.
MTT cell proliferation assay of compound 4 against the HT-29 cancer cell line.
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Scheme 1.
Synthesis of compounds 1–4.
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Scheme 2.
Proposed mechanism for the formation of the oxidised compounds in DMSO.
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Table 1
Mass spectroscopic data of ligands and compounds.
(A) Reduced Schiff base, K[Sal-L-tryp), and compounds 1-4.
Species Exact
Mass [g
mol-1]
Species formed in the spectrometer m/z Relative Intensity
Reduced Schiff base # 310.13
[M + H]+ 311.08 100.00
[M − CHO3 + H]+ 242.42 13.04
[2M + H]+ 620.36 12.77
[3M + H]+ 930.39 5.02
[4M + H]+ 1240.92 3.92
K[(Sal-L-tryp)] # 346.07
[M + H]+ 344.05 39.65
[M − OH − K + H]+ 300.03 100.00
[M − OH − O − K + H]+ 205.20 50.43
[M − COO − K + H]+ 242.62 64.65
[M − COO − OH − K + H]+ 262.12 1.51
[M − C7H6O − K + H]+ 281.14 46.08
[VO(Sal-L-tryp)(MeATSC)] # 666.14
[M + H]+ 666.17 100.00
[M − C2H5N2S + H]+ 577.08 33.10
[M − C17H17N3 + H]+ 405.14 31.86
[MeATSC + H]+ 292.14 54.60
[VO(Sal-L-tryp)(N-Ethhymethohcarbthio)] †
626.13 [M − H]- 624.87 100.00
[M − C11H10N2O − H]- 431.90 64.75
[M − C11H15N3O2S - H]- 407.85 20.99
[[C11H15N3O2S − C8H7N] − H]- 287.88 12.70
[N-Ethhymethohcarbthio − H]- 252.00 25.74
[VO(Sal-L-tryp)(acetylethTSC)] # 601.09
[M + H]+ 600.25 2.71
[M − C3H7NS + H]+ 513.57 100.00
[M − C7H5NO + H]+ 482.38 37.11
[M − C17H15N2O + H]+ 336.06 4.13
(B) Oxidised products isolated from compounds 1 and 3.
Species Exact
Mass [g
mol-1]
Species formed in the spectrometer m/z Relative Intensity
Proposed [VO(Sal-L-tryp)(DMSO)(OH)] a, #
intermediate
468.06 [M + H]+ 468.60 1.67
[M − OH − DMSO − C8H7N + H]+ 242.41 100.00
[M − OH + H]+ 451.05 48.25
[[V2O3(Sal-L-tryp)2] + H]+ 763.68 30.06
[[V2O3(Sal-L-tryp)2(H2O)] + H]+ 776.77 49.36
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(A) Reduced Schiff base, K[Sal-L-tryp), and compounds 1-4.
Species Exact
Mass [g
mol-1]
Species formed in the spectrometer m/z Relative Intensity
[[V2O3(Sal-L-tryp)2(DMSO)2] + H]+ 918.28 3.13
Proposed [VO(Sal-L-tryp)(DMSO)(OH)] b, #
intermediate
468.06 [M + H]+ 470.01 0.50
[N-Ethhymethohcarbthio + H]+ 252.26 100.00
[M − OH + H]+ 451.96 2.97
[M − OH + N-Ethhymethohcarbthio +
H]+
702.75 2.15
[[V2O3(Sal-L-tryp)2 + H]+ 763.22 0.74
[[V2O3(Sal-L-tryp)2(H2O)] + H]+ 775.40 1.08
[[V2O3(Sal-L-tryp)2(DMSO)2] + H]+ 916.44 0.75
#positive mode
†
negative mode
aproposed vanadium(V) intermediate obtained from compound 1
bproposed vanadium(V) intermediate obtained from compound 3
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Table 2
Crystal data and structure refinement for acetylethTSC.
Identification code acetylethTSC
Empirical formula C8H12N4S2
Formula weight 228.34
Temperature 90.0(5) K
Wavelength 1.54178 Å
Crystal system, space group Monoclinic, C2/c
Unit cell dimensions a = 10.4549(10) Å, α = 90°
b = 10.8970(10) Å, β = 91.544(5)°
c = 18.7694(15) Å, γ = 90°
Volume 2137.6(3) Å3
Z, Calculated density 8, 1.419 Mg/m3
Absorption coefficient 4.251 mm-1
F(000) 960
Crystal size 0.18 × 0.17 × 0.09 mm
Theta range for data collection 5.8 to 68.1°
Limiting indices -12<=h<=12, -12<=k<=13, -22<=l<=22
Reflections collected / unique 8017 / 1901 [Rint = 0.026]
Completeness to theta = 66.6° 99.1%
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 0.701 and 0.515
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 1901 / 0 / 136
Goodness-of-fit on F2 1.065
Final R indices [I>2σ(I)] R1 = 0.0276, wR2 = 0.0691
R indices (all data) R1 = 0.0312, wR2 = 0.0715
Extinction coefficient 0.00011(3)
Largest diff. peak and hole 0.257 and -0.262 e Å -3
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Table 5
Chemical shifts and percentages of species of DMSO-d6 solutions for compounds 1–4 after being oxidised for
24 hours.
Compound δ [ppm] (%) δ [ppm] (%) δ [ppm] (%)
1 −480.5 (7.1) −541.4 (92.9)
2 −481.9 (9.2) −542.2 (90.8)
3 −467.7 (41.7) −541.0 (47.9) −559.3(10.4)
4 −481.9 (6.9) −541.2 (93.1)
Eur J Inorg Chem. Author manuscript; available in PMC 2013 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Lewis et al. Page 32
Table 6
UV-visible spectroscopic data for compounds 1–4.
Compound λ [nm] ε [M-1cm-1] Assignments
1
558 44 LMCT (p → d transition)
758 27 d → d transition
2
266 74835 π → π* (thioamide moiety)
292 (sh) 17954 π → π* (thioamide moiety)
316 (sh) 10046 n → π* (aromatic rings)
388 15013 π → π* (azomethine chromophore)
550 54 LMCT (p → d transition)
592 (sh) 45 d → d transition
756 28 d → d transition
3
270 (sh) 10984 π → π* (thioamide moiety)
288 (sh) 13874 π → π* (thioamide moiety)
330 24837 n → π* (aromatic rings)
390 (sh) 18250 π → π* (azomethine chromophore)
620 852 d → d transition
4
276 21969 π → π* (thioamide moiety)
352 14227 n → π* (aromatic rings)
558 80 LMCT (p → d transition)
590 (sh) 70 d → d transition
756 38 d → d transition
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